Introduction
CytoDyn (CYDY) shares have been on a tear over the last few months, moving from just under $0.30 in December to an intraday high of ~$3.50 merely months later. From signing a commercialization deal with Vyera to launching a promising basket trial in over 20 different metastatic cancers to jumping on the COVID-19 train, showing impressive anecdotal results in resolving patients’ “cytokine storms,” there has been much action at CytoDyn.
Amid much excitement, a share price drastically up within months, and what could be perceived as hype, a short seller’s report attempted